ACXP · Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals operates in the high-risk, high-reward biopharmaceutical sector, targeting a critical unmet need in antibiotics for Gram-positive infections amid the global antimicrobial resistance crisis. Its lead candidate, ibezapolstat, advances into a new recurrent C. difficile infection program with a 20-patient pilot trial starting Q2 2026, aiming toward Phase 3 and LPAD approval, positioning it as late-stage with defined regulatory pathways but no approved products or revenue disclosed. The April 2026 financing combined a $2.5 million registered direct offering of 825,085 shares/pre-funded warrants at $3.03 with concurrent series H warrants for 1,650,170 shares at $2.78 exercise price, closing April 16. This S-1 registers resale of warrant shares by institutional selling stockholders like Armistice Capital (18.6% beneficial owner) and others, with no direct proceeds to Acurx from resales but potential $4.6 million cash inflow if fully exercised over 24 months post-effectiveness, subject to 4.99%/9.99% ownership blockers and cashless exercise options. Proceeds would fund general corporate needs amid going concern warnings in CohnReznick's March 2026 audit report, highlighting liquidity pressures typical for clinical-stage biopharmas burning cash on R&D without product sales. The Lincoln Park ELOC, entered May 2025 for up to $12 million, has delivered $7.3 million via 1.835 million shares across prior S-1s, providing flexible non-dilutive capital but increasing share count and dilution risks. Management, led by CEO David P. Luci and CFO Robert Shawah, signed the May 4, 2026 filing from New York, with a classified board and anti-takeover provisions like no stockholder written consents and 66 2/3% supermajority amendments deterring activism. As an emerging growth and smaller reporting company, Acurx benefits from scaled-back disclosures, easing IPO burdens but potentially obscuring full financials. Investor risks center on clinical binary outcomes, funding needs post-warrant expiry, Nasdaq compliance amid volatility (April 29 price $2.02 used for fee calc), and competition in antibiotics where novel mechanisms offer moat but trial failures could wipe value. Recent lock-ups and variable transaction bans through April 2027 (with ATM/ELOC exceptions) stabilize capital access but limit flexibility. Overall, this resale registration facilitates warrant liquidity for investors while enabling Acurx potential non-dilutive cash for ibezapolstat advancement, critical for bridging to pivotal data in a cash-constrained profile.